Comparative Pharmacology
Head-to-head clinical analysis: CLOTRIMAZOLE versus NYSTAFORM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOTRIMAZOLE versus NYSTAFORM.
CLOTRIMAZOLE vs NYSTAFORM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clotrimazole inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol biosynthesis and increasing membrane permeability.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity and cause leakage of intracellular contents, leading to fungal cell death.
Topical: Apply thin layer to affected area twice daily for 2-4 weeks. Oral troche: 10 mg troche dissolved slowly in mouth 5 times daily for 14 days. Vaginal: One 100 mg suppository intravaginally at bedtime for 7 days, or 200 mg suppository for 3 days, or 500 mg single dose.
1 tablet (nystatin 100,000 units) orally three times daily after meals. Each tablet should be allowed to dissolve slowly in the mouth.
None Documented
None Documented
Clinical Note
moderateClotrimazole + Tranilast
"The risk or severity of adverse effects can be increased when Clotrimazole is combined with Tranilast."
Clinical Note
moderateClotrimazole + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Clotrimazole is combined with Tolfenamic acid."
Clinical Note
moderateClotrimazole + Nimesulide
"The risk or severity of adverse effects can be increased when Clotrimazole is combined with Nimesulide."
Clinical Note
moderateTerminal half-life is approximately 3-6 hours; due to rapid hepatic metabolism and extensive tissue distribution, clinical effects persist longer than plasma levels suggest.
Plasma half-life is not measurable due to negligible systemic absorption. Topical or oral administration results in local action only; no systemic half-life is clinically relevant.
Primarily fecal (biliary) as unchanged drug and metabolites; minimal renal excretion (<1% unchanged).
Nystatin is not absorbed from the gastrointestinal tract, intact skin, or mucous membranes. After oral administration, it is excreted almost entirely unchanged in feces (over 99%). Minimal renal excretion occurs (less than 1%).
Category A/B
Category C
Antifungal
Antifungal
Clotrimazole + Risedronic acid
"The risk or severity of adverse effects can be increased when Clotrimazole is combined with Risedronic acid."